Kintor Pharmaceutical Ltd is an investment holding company primarily engaged in the research and development of innovative medicine products. The Company's products are dedicated to addressing disease areas that have not met clinical needs, and its pipeline mainly covers indications of dermatology (such as androgenetic alopecia, acne vulgaris) and indications of tumors. The Company has two core drugs in the dermatology field, KX-826 and GT20029. The Company's other disease areas include metastatic castration-resistant prostate cancer (mCRPC), liver cancer, idiopathic pulmonary fibrosis, malignant blood diseases and various solid tumors.

Employees

123

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
17/07/26	US$0.2305	-6.51%	5,000

Delayed Quote OTC Markets

More quotes

Income Statement and Estimates

More financial data

Annual profits - Rate of surprise

Company calendar

Market Closed - OTC Markets Other stock markets 16:21:32 17/07/2026 BST			5-day change	1st Jan Change
0.2304 ^USD	-6.51%		-6.49%	+6.71%

06-11	Kintor Pharma Posts Positive Interim Safety Data for Whitening Agent KT-939	MT
06-10	Kintor Pharmaceutical Limited Announces Positive Interim Result in Long-Term Human Safety Trial of Kt-939 and Commences Registration Application for New Raw Material	CI

Market Cap	739M 109M 95.22M 87.87M 80.99M 153M 10.49B 156M 1.05B 413M 5.14B 409M 400M 17.69B	P/E 2024	-2.53x	P/E 2025	-3.96x
Enterprise Value	792M 117M 102M 94.28M 86.9M 164M 11.26B 167M 1.13B 443M 5.51B 439M 429M 18.98B	EV / Sales 2024	75,794,130x	EV / Sales 2025	28,245,180x
Free-Float	83.05%	Yield 2024 *	-	Yield 2025	-

06-11	Kintor Pharma Posts Positive Interim Safety Data for Whitening Agent KT-939	MT
06-10	Kintor Pharmaceutical Limited Announces Positive Interim Result in Long-Term Human Safety Trial of Kt-939 and Commences Registration Application for New Raw Material	CI
05-28	Kintor pharmaceutical says CEO via wholly owned co increases shareholding by 2.51 million shares	RE
05-27	Kintor Pharmaceutical Auditor to Retire; Shares Drop 7%	MT
05-26	Kintor Pharmaceutical Limited Announces Change of Address of Principal Place of Business in Hong Kong, with Effect from 1 June 2026	CI
04-21	Kintor Pharmaceutical's 2026 Sales Jump Past 2025 Full-Year Level	MT
04-20	Kintor Pharmaceutical says ytd 2026 sales revenue at RMB34 million	RE
04-20	Kintor Pharmaceutical Limited Provides Sales Guidance for the Year 2026	CI
04-20	Kintor Pharmaceutical Limited Announces Preliminary Sales Results for the Year to Date Ended April 20, 2026	CI
03-30	Kintor Pharmaceutical Limited Reports Earnings Results for the Full Year Ended December 31, 2025	CI
03-19	Kintor Pharma's Androgenetic Alopecia Drug Meets Primary Endpoint in Phase 3 Trial; Shares Plunge 21%	MT
03-18	Kintor pharmaceutical says pharma's KX-826 phase III trial in China reaches primary endpoint	RE
03-18	Kintor Pharmaceutical Limited Announces Phase III Clinical Trial Results For KX-826 Tincture 1.0% For Male Adult AGA In China	CI

28/10/23	Kintor Pharmaceutical : Pharma Announces Publication of Phase Ib/II Data from GT90001 and Nivolumab Combination Therapy for Advanced HCC in BMC Medicine	PU
11/10/23	Kintor Pharmaceutical : Pharma Announces the Approval of Phase II Clinical Trial of Hedgehog/SMO Inhibitor GT1708F for Treatment of IPF in China	PU
28/08/23	Kintor Pharmaceutical : Pharma Announces 2023 Interim Results and Recent Business Highlights	PU
22/08/23	Kintor Pharmaceutical : Pharma Announces Completion of Patient Enrollment in Phase II Clinical Trial of GT20029 for Treatment of Androgenetic Alopecia in China	PU
20/07/23	Kintor Pharma Announces Completion of First Patient Enrollment in KX-826 Long-term Safety Phase III Trial for Treatment of AGA	AQ

Kintor Pharmaceutical Limited Share Price OTC Markets

Stocks

KNTPF

KYG5273B1077

Biotechnology & Medical Research

Valuation: Kintor Pharmaceutical Limited

Chart: Kintor Pharmaceutical Limited

Latest news : Kintor Pharmaceutical Limited

Press Releases: Kintor Pharmaceutical Limited

Quotes and Performance

Course Extremes

Managers and Directors: Kintor Pharmaceutical Limited

Bio Therapeutic Drugs

Financials

Company Profile

Quotes

Income Statement and Estimates

Annual profits - Rate of surprise

1 day	-6.51%
1 week	-6.49%
Current month	-32.60%
1 month	-32.60%
3 months	-23.17%
6 months	-30.80%
Current year	+6.71%

1 week	0.23	0.23
1 month	0.23	0.25
Current year	0.23	0.57
1 year	0.22	0.57
3 years	0.08	0.57
5 years	0.08	11.8
10 years	0.08	11.8

Manager	Title	Age	Since
You Zhi Tong CEO	Chief Executive Officer	64	23/03/2009
Ming Ming Cheung DFI	Director of Finance/CFO	49	13/04/2023
Hong Long Lu CTO	Chief Tech/Sci/R&D Officer	49	31/08/2020

Director	Title	Age	Since
You Zhi Tong CHM	Chairman	64	23/03/2009
Min Xu BRD	Director/Board Member	61	11/08/2019
Yeung Wai Yim BRD	Director/Board Member	62	11/08/2019

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
KINTOR PHARMACEUTICAL LIMITED	-6.51%	-6.49%	-	-	109M
WUXI APPTEC CO., LTD.	-7.17%	-4.39%	+45.51%	+79.00%	52.1B
ARGENX SE	+0.24%	-1.54%	+53.22%	+71.85%	53.83B
INSMED INCORPORATED	+0.80%	-6.31%	+3.98%	+423.29%	23.48B
BIONTECH SE	-0.09%	-0.01%	-17.62%	-14.67%	23.13B
WUXI BIOLOGICS (CAYMAN) INC.	-5.95%	-2.58%	+30.67%	-9.58%	19.36B
GENMAB A/S	-1.14%	+0.03%	+31.57%	-30.42%	17.56B
PHARMAESSENTIA CORPORATION	-5.16%	-7.00%	+168.44%	+306.37%	15.2B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	-6.91%	-5.83%	+26.53%	+636.97%	14.83B
EXELIXIS, INC.	+0.43%	-1.03%	+24.63%	+191.40%	14.06B
Average	-3.15%	-2.62%	+40.77%	+183.80%	25.95B
Weighted average by Cap.	-2.80%	-2.36%	+40.12%	+144.11%

	2024	2025
Net sales	5 0.74 0.64 0.59 0.55 1.03 71.04 1.06 7.11 2.8 34.79 2.77 2.71 119.77	32.68 4.82 4.21 3.89 3.58 6.76 464.33 6.91 46.47 18.28 227.41 18.11 17.71 782.85
Net income	-155M -22.91M -20.02M -18.48M -17.03M -32.1M -2.21B -32.81M -221M -86.86M -1.08B -86.04M -84.15M -3.72B	-200M -29.52M -25.8M -23.81M -21.94M -41.36M -2.84B -42.28M -285M -112M -1.39B -111M -108M -4.79B
Net Debt	-15.68M -2.31M -2.02M -1.87M -1.72M -3.24M -223M -3.31M -22.3M -8.77M -109M -8.69M -8.5M -376M	53.86M 7.95M 6.94M 6.41M 5.91M 11.13M 765M 11.38M 76.59M 30.12M 375M 29.84M 29.19M 1.29B